Literature DB >> 29784848

In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis.

Carolyn Shoen1, Michelle DeStefano2, Barry Hafkin3, Michael Cynamon1,4.   

Abstract

The in vitro activity of contezolid (MRX-I) against clinical isolates of Mycobacterium tuberculosis was evaluated using a microtiter broth dilution assay. MRX-I was as effective as linezolid (LZD) in vitro MRX-I and LZD were subsequently studied in BALB/c mice infected intranasally with M. tuberculosis Erdman. MRX-I and LZD at 100 mg/kg significantly reduced the bacterial load in lungs compared to the untreated early and late controls.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Mycobacterium tuberculosis; in vitro; mouse model; oxazolidinones

Mesh：

Substances：

Year:  2018        PMID： 29784848      PMCID： PMC6105800          DOI： 10.1128/AAC.00493-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.

Authors:  M H Cynamon; S P Klemens; C A Sharpe; S Chase
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis.

Authors:  Armand Van Deun; Aung Kya Jai Maug; Md Abdul Hamid Salim; Pankaj Kumar Das; Mihir Ranjan Sarker; Paul Daru; Hans L Rieder
Journal:  Am J Respir Crit Care Med       Date:  2010-05-04       Impact factor: 21.405

3.  Single- and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects.

Authors:  Paul B Eckburg; Yigong Ge; Barry Hafkin
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

4.  Linezolid for treatment of chronic extensively drug-resistant tuberculosis.

Authors:  Myungsun Lee; Jongseok Lee; Matthew W Carroll; Hongjo Choi; Seonyeong Min; Taeksun Song; Laura E Via; Lisa C Goldfeder; Eunhwa Kang; Boyoung Jin; Hyeeun Park; Hyunkyung Kwak; Hyunchul Kim; Han-Seung Jeon; Ina Jeong; Joon Sung Joh; Ray Y Chen; Kenneth N Olivier; Pamela A Shaw; Dean Follmann; Sun Dae Song; Jong-Koo Lee; Dukhyoung Lee; Cheon Tae Kim; Veronique Dartois; Seung-Kyu Park; Sang-Nae Cho; Clifton E Barry
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

5.  Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis.

Authors:  D R Ashtekar; R Costa-Periera; T Shrinivasan; R Iyyer; N Vishvanathan; W Rittel
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Nov-Dec       Impact factor: 2.803

6.  Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.

Authors:  M R Barbachyn; D K Hutchinson; S J Brickner; M H Cynamon; J O Kilburn; S P Klemens; S E Glickman; K C Grega; S K Hendges; D S Toops; C W Ford; G E Zurenko
Journal:  J Med Chem       Date:  1996-02-02       Impact factor: 7.446

7.  Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721.

Authors:  A M Slee; M A Wuonola; R J McRipley; I Zajac; M J Zawada; P T Bartholomew; W A Gregory; M Forbes
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

Review 8.  New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile.

Authors:  Mikhail F Gordeev; Zhengyu Y Yuan
Journal:  J Med Chem       Date:  2014-04-16       Impact factor: 7.446

9.  Linezolid-Associated Optic Neuropathy in Drug-Resistant Tuberculosis Patients in Mumbai, India.

Authors:  Salil Mehta; Mrinalini Das; Chinmay Laxmeshwar; Sylvie Jonckheere; Sein Sein Thi; Petros Isaakidis
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240
  9 in total
  11 in total

1.  Concentration-response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent.

Authors:  Junzhen Wu; Kun Wang; Yuancheng Chen; Hong Yuan; Li Li; Jing Zhang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-08-13       Impact factor: 2.745

Review 2.  Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.

Authors:  Adetomiwa A Adeniji; Kirsten E Knoll; Du Toit Loots
Journal:  Appl Microbiol Biotechnol       Date:  2020-05-05       Impact factor: 4.813

3.  Pharmacokinetics and Disposition of Contezolid in Humans: Resolution of a Disproportionate Human Metabolite for Clinical Development.

Authors:  Xiaojie Wu; Jian Meng; Hong Yuan; Dafang Zhong; Jicheng Yu; Guoying Cao; Xingdang Liu; Beining Guo; Yuancheng Chen; Yi Li; Yaoguo Shi; Mikhail F Gordeev; Jufang Wu; Jing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2021-08-16       Impact factor: 5.191

4.  Drug Degradation Caused by mce3R Mutations Confers Contezolid (MRX-I) Resistance in Mycobacterium tuberculosis.

Authors:  Rui Pi; Xiaomin Chen; Jian Meng; Qingyun Liu; Yiwang Chen; Cheng Bei; Chuan Wang; Qian Gao
Journal:  Antimicrob Agents Chemother       Date:  2022-10-03       Impact factor: 5.938

Review 5.  New Drugs for the Treatment of Tuberculosis.

Authors:  Elisa H Ignatius; Kelly E Dooley
Journal:  Clin Chest Med       Date:  2019-12       Impact factor: 4.967

Review 6.  Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms.

Authors:  Despoina Koulenti; Elena Xu; Andrew Song; Isaac Yin Sum Mok; Drosos E Karageorgopoulos; Apostolos Armaganidis; Sotirios Tsiodras; Jeffrey Lipman
Journal:  Microorganisms       Date:  2020-01-30

Review 7.  Advances in Key Drug Target Identification and New Drug Development for Tuberculosis.

Authors:  Jie Mi; Wenping Gong; Xueqiong Wu
Journal:  Biomed Res Int       Date:  2022-02-25       Impact factor: 3.411

Review 8.  Antibiotics in the clinical pipeline in October 2019.

Authors:  Mark S Butler; David L Paterson
Journal:  J Antibiot (Tokyo)       Date:  2020-03-10       Impact factor: 2.649

Review 9.  Drug Discovery for Mycobacterium tuberculosis Using Structure-Based Computer-Aided Drug Design Approach.

Authors:  Murtala A Ejalonibu; Segun A Ogundare; Ahmed A Elrashedy; Morufat A Ejalonibu; Monsurat M Lawal; Ndumiso N Mhlongo; Hezekiel M Kumalo
Journal:  Int J Mol Sci       Date:  2021-12-09       Impact factor: 5.923

Review 10.  Contezolid: First Approval.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2021-09       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.